New hope for Tough-to-Treat blood cancer: MK-1045 enters human trials
NCT ID NCT05579132
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MK-1045 (CN201) in people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking how well the drug works. About 203 participants, aged 2 and older, will receive the drug by IV infusion over several cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1045 (also called CN201), a drug given by IV infusion
What this could lead to
If it works, this could provide a new treatment option for people with B-ALL whose cancer has returned or stopped responding to current therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause serious side effects. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)
RECRUITINGTianjin, Tianjin Municipality, 301617, China
Contact Phone: •••-•••-••••
-
Henan Cancer Hospital-hematology department ( Site 0002)
RECRUITINGZhengzhou, Henan, 450008, China
Contact Phone: •••-•••-••••
-
Southern Medical University Nanfang Hospital ( Site 0004)
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-••••
-
The Affiliated Hospital of Xuzhou Medical University ( Site 0007)
ACTIVE_NOT_RECRUITINGXuzhou, Jiangsu, 221002, China
-
The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)
COMPLETEDHangzhou, Zhejiang, 310003, China
-
The First Hospital of Harbin ( Site 0005)
RECRUITINGHarbin, Heilongjiang, 150010, China
Contact Phone: •••-•••-••••
-
The Second Affiliated Hospital of Third Military Medical University ( Site 0008)
RECRUITINGChongqing, Chongqing Municipality, 400037, China
Contact Phone: •••-•••-••••
-
The Second Hospital of Hebei Medical University ( Site 0003)
RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-••••
-
Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-••••
-
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-••••
-
West China Second University Hospital, Sichuan University ( Site 0011)
COMPLETEDChengdu, Sichuan, 610000, China